Business Highlights and Fiscal 2025 to Fiscal 2024 Second Quarter Comparisons Consolidated revenue of $600.3 million, compared to $732.6 million in the prior-year quarter, mainly attributable to lower ...
Imdusiran data from IM-PROVE I and IM-PROVE II Phase 2a clinical trials to be presented at upcoming AASLD – The Liver Meeting 2024 Multiple-ascending doses of AB-101 in healthy subjects in the Phase ...